Fact Sheet: Parkinson’s Disease Clinical Development
Parkinson’s Disease CRO Expertise for Complex Clinical Trials
As Parkinson’s disease research advances toward earlier intervention, disease modification, and prevention-focused approaches, sponsors need a partner with deep therapeutic expertise and the operational capabilities to execute increasingly complex studies.
P95 Julius Clinical combines scientific leadership, established relationships with leading Parkinson’s investigators, and global clinical operations expertise to support Parkinson’s disease programs across all phases of development. From biomarker and imaging strategies to digital endpoints and real-world evidence generation, we help sponsors navigate the unique challenges of Parkinson’s research.
Download our Parkinson’s Disease Fact Sheet to learn how we support recruitment and retention, endpoint strategy, trial execution, and evidence generation across the development lifecycle. Learn how our experience across symptomatic, disease-modifying, and prevention-focused studies, including our role supporting The Michael J. Fox Foundation’s Path to Prevention platform trial, reflects our commitment to advancing Parkinson’s disease research.
Complete the form to access the fact sheet.
Related resources
Case Study: Delivering Early Enrollment Against Aggressive Timelines in a Phase II Parkinson’s Disease Study
How a Site-Centric Delivery Model Accelerated Study Start-Up When a Phase II Parkinson’s disease study faced aggressive start-up and enrollment targets, the study team was tasked with achieving first patient consent within just eight weeks of f...